within Pharmacolibrary.Drugs.N_NervousSystem.N07B_DrugsUsedInAddictiveDisorders.N07BC01_Buprenorphine;

model Buprenorphine
  extends Pharmacolibrary.Drugs.ATC.N.N07BC01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N07BC01</td></tr><td>route:</td><td>sublingual</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Buprenorphine is a semi-synthetic opioid used primarily in the treatment of opioid dependence and chronic pain. It is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is approved for use in opioid substitution therapy and is available in multiple formulations including sublingual tablets, subcutaneous injection, and transdermal patches.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects, mixed sex, after single sublingual administration.</p><h4>References</h4><ol><li><p>Elkader, A, &amp; Sproule, B (2005). Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. <i>Clinical pharmacokinetics</i> 44(7) 661–680. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544070-00001&quot;>10.2165/00003088-200544070-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15966752/&quot;>https://pubmed.ncbi.nlm.nih.gov/15966752</a></p></li><li><p>Lim, SCB, et al., &amp; Krishnarajah, J (2019). The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. <i>Pain medicine (Malden, Mass.)</i> 20(1) 143–152. DOI:<a href=&quot;https://doi.org/10.1093/pm/pnx321&quot;>10.1093/pm/pnx321</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29309700/&quot;>https://pubmed.ncbi.nlm.nih.gov/29309700</a></p></li><li><p>Gu, M, et al., &amp; Zhu, X (2023). Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization. <i>Frontiers in pharmacology</i> 14 1089862–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2023.1089862&quot;>10.3389/fphar.2023.1089862</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36744255/&quot;>https://pubmed.ncbi.nlm.nih.gov/36744255</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Buprenorphine;
